PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth Article (Faculty180)

cited authors

  • Bhattacharjee, Sayani; Sullivan, Matthew J; Wynn, Rebecca R; Demagall, Alex; Hendrix, Andrew S; Sindhwani, Puneet; Petros, Firas G; Nadiminty, Nagalakshmi


  • Management of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in most cases. Chemotherapy reduces tumor recurrence after resection, but debilitating toxicities render a large percentage of patients ineligible. Recently approved immunotherapy can improve outcomes in only a third of metastatic BLCA patients. Therefore, more options for therapy are needed. In this study, we explored the efficacy of PARP inhibitors (PARPi) as single agents or as combinations with platinum therapy.

publication date

  • 2022

published in

start page

  • 312


  • 22